US-based cell therapy developer SQZ Biotechnology closed an oversubscribed $72m series C round today that included biotechnology producer Illumina and internet and technology conglomerate Alphabet.
Insurance provider Orient Life also contributed to the round, as did Everblue, Invus, Viva Ventures Biotech, Bridger Healthcare Partners, Global Health Science Fund, NanoDimension, Polaris Partners and JDRF T1D Fund, managed by diabetes-focused charity JDRF.
Illumina and Alphabet invested in the round through corporate venturing subsidiaries Illumina Ventures and GV respectively.
SQZ Biotechnology has developed a platform to create cell therapies that utilise the human body’s immune system. Its lead candidate is initially focused on human papillomavirus-positive cancer, with plans to target solid tumours across cancer indications in future.
The company is also working on a treatment for type 1 diabetes and other autoimmune conditions, and is commercialising research by Klavs Jensen, Robert Langer and Armon Sharei at Massachusetts Institute of Technology.
The series C capital will fund the further development of treatments for solid tumours and autoimmune disorders. JDRF T1D Fund invested an undisclosed sum in SQZ in December 2017, though it is not clear whether this formed part of the series C round.
SQZ closed a $24m series B round in December 2016 with an $8m tranche backed by GV and Quark Venture, three months after NanoDimension and Polaris Partners co-led a $16m first close. Polaris had led a $5m series A round in 2015 that included 20/20 Healthcare Partners.
Bridger Healthcare partner Marc Elia and Zafi Avnur, chief scientific officer for Quark Venture, the VC firm that manages the Global Health Science Fund, have joined SQZ’s board of directors in connection with the series C round.